Replies to post #70454 on Anavex Life Sciences Corp (AVXL)

[frrol]

Unlike in the Part A poster last November, the company chose not to do comparisons to the AIBL-ROCS study time-points (presumably interpolated by the company), preferring to just state that "scores were maintained through 31 weeks". There are in fact slight falls discernable in the graphs so it would have been particularly helpful to provide the time-point comparisons. This would empirically show the relative benefit to typical disease progression, and make the company's argument more tenable. (Without it the company's argument looks risible to critics, hence that AF tweet.)

We're going to get dinged for such stuff. I suspect the company will fix that and provide comparisons by the 38 or 52 week release. Longer-term data makes the comparison more robust anyway. (Though again the company did it for the 5 week Part A...)